Stuart Therapeutics will be attending and presenting at major life sciences conferences this fall:

  • Stuart Therapeutics will be presenting at the BioFlorida Annual Conference October 15th and 16th in the conference’s BioPitch competition in Ft. Lauderdale, Florida. The BioFlorida conference will be held at the Westin Ft. Lauderdale Beach Resort.
  • The company will also be attending the annual OIS Meeting, held this year in Chicago at the Marriott Marquis, Chicago, October 25th.
  • Stuart Therapeutics has been invited to present as a Next Generation Company at the BIO-Europe annual conference, held this year in Copenhagen, Denmark, November 5th – 7th.

We look forward to seeing you and discussing our progress at these conferences.


For partnering inquiries, or other questions, please contact us below:

Stuart Therapeutics is committed to rapidly developing the power of the PolyCol and TheraCol platform technologies to deliver transformative, enhanced medicines to the widest range of applicable diseases as quickly as possible.

The PolyCol platform spans a wide range of disease areas. While we may expand into other disease areas in the future, our current focus is on ophthalmic conditions and certain cancers, which enables a cost-efficient discovery and development strategy. We control worldwide exclusive commercialization rights to PolyCol and its applications across a wide array of medical conditions.

The patented platform technology that is embodied in the ST-101 bioresorbable insert can be adapted to a wide variety of drug delivery applications. We control the worldwide exclusive commercialization rights to this technology.

Stuart Therapeutics is pleased to consider development partners for the extension of PolyCol and TheraCol into new therapeutic areas. We are currently considering partnerships in the following areas:

Uroepithelial Cancer
Other Intraluminal Cancer Conditions
Retinal Disease
Corneal Surface Disease

Eric Schlumpf
President and CEO
Cell: 206.228.2781

Shawn DeLorey
SVP, Program Management and Corporate Development
Cell: 617.513.2701